NCT06624644 2026-04-22
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
Clinical Trials
15 trialsNCT07226999 2026-04-20
Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
Pfizer
Phase 2/3 Recruiting
NCT07392892 2026-04-13
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer
Phase 2/3 Recruiting
NCT07472153 2026-03-16
PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer
N.N. Alexandrov National Cancer Centre
Phase 2/3 Recruiting
NCT07454720 2026-03-06
A Randomized, Double-blind, Placebo-controlled, Multicenter Phase II/III Clinical Study of Adebrelimab in Combination With SHR-8068 and Chemoradiotherapy as Perioperative Therapy for Locally Advanced Rectal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Phase 2/3 Not yet recruiting
NCT06860269 2026-02-10
GRAALL-2024
Assistance Publique - Hôpitaux de Paris
Phase 2/3 Recruiting
NCT04681417 2025-11-28
RETINO 2018
Institut Curie
Phase 2/3 Recruiting
NCT06341998 2025-09-19
SCRRYST
Shandong First Medical University
Phase 2/3 Completed
NCT07145333 2025-09-08
Drug-SNP
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT06958432 2025-08-07
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 2/3 Recruiting
NCT01064466 2025-07-24
Drugs-SNPs
Medicine Invention Design, Inc
Phase 2/3 Active not recruiting
NCT06232434 2025-06-22
ИНТЕЛОН-02
Research Institute for Physical Chemical Problems of the Belarusian State University
Phase 2/3 Recruiting
NCT04082364 2025-06-08
MAHOGANY
MacroGenics
Phase 2/3 Completed
NCT07000253 2025-06-02
OMEC-5
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2/3 Not yet recruiting
NCT02807181 2025-05-09
SIRCCA
Sirtex Medical
Phase 2/3 Terminated